Compugen to Present at Upcoming Antibody Industrial Symposium
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France.
2024年6月17日，以色列霍隆，納斯達克（Nasdaq: CGEN）（TASE: CGEN）生物公司Compugen（複查源）是一家臨床階段的癌症免疫療法公司，並是計算目標發現的先驅，在2024年6月20日至21日舉行的抗體工業研討會上，該公司的高級副總裁Pierre Ferre博士將介紹有關TIGIT單克隆和雙克隆抗體的臨床劑量選擇的案例研究。地點在法國蒙彼利埃。
Event: 12th Antibody Industrial Symposium, Montpellier, France
Date: Friday, June 21, 2024
Presenter: Pierre Ferré, Ph.D., SVP, Preclinical Development and Corporate Operations, Compugen
Presentation title: Case study on clinical dose selection for TIGIT monospecific and bispecific antibodies
活動：12th抗體工業研討會，法國蒙彼利埃
日期：2024年6月21日星期五
報告人：Compugen的預臨床開發和企業運營高級副總裁Pierre Ferre博士
演講題目關於TIGIT單克隆和雙克隆抗體的臨床劑量選擇案例研究
About Compugen
關於Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Compugen是一家臨床階段的治療性發現和開發公司，利用其廣泛適用的預測性計算發現能力，鑑定新的藥物靶點和生物學途徑，用於開發癌症免疫治療。Compugen已開發出兩個專有藥物候選：COM701，一種潛在的第一類抗-PVRIG抗體和COM902，一種潛在的最佳抗-TIGIT抗體，用於實體腫瘤的治療。rilvegostomig是一種PD-1/TIGIT雙特異性抗體，其TIGIT成分來自Compugen的臨床階段抗TIGIT抗體COM902，在通過許可協議開發雙特異性和多特異性抗體方面由阿斯利康開發第3期。此外，公司的早期階段的免疫腫瘤學療法管道包括針對各種免疫耐受機制的治療方案，其中最先進的療法是授權給吉利德的COM503。COM503是一種潛在的第一類高親和力抗體，可阻斷IL-18結合蛋白和IL-18之間的相互作用，從而在腫瘤微環境中釋放天然IL-18以抑制腫瘤生長。Compugen總部位於以色列，舊金山，加州，其他辦事處。Compugen的股票在NASDAQ和Tel Aviv Stock Exchange上掛牌，股票代碼爲CGEN。
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: [email protected]
Tel: +1 (628) 241-0071
公司聯繫方式：
Yvonne Naughton博士
投資者關係和企業溝通主管
電子郵件：[email protected]
電話：+1 (628) 241-0071
SOURCE Compugen Ltd.
消息來源：Compugen Ltd.
譯文內容由第三人軟體翻譯。